Development of the first of its kind medication for combined treatment of viral and bacterial conjunctivitis.

Pharma Holdings (https://www.pharmaholdings.no) is developing eyedrops for the treatment of conjunctivitis caused by both bacteria and viruses based on LTX-109. LTX-109 is a novel antimicrobial synthetic peptide with a fast-acting membrane lysing mode of action. It is a short cationic synthetic p...